Martin Sean 4
Research Summary
AI-generated summary
Generate Biomedicines (GENB) GC Sean Martin Receives Award
What Happened Sean Martin (Chief Legal Officer & General Counsel) was granted 190,034 derivative securities on 2026-02-26. The grant was reported on a Form 4 filed 2026-03-02. The reported acquisition price is $0.00, meaning no cash was paid at grant — this is a compensation award (option/derivative), not an open-market purchase or sale.
Key Details
- Transaction date: February 26, 2026; Filing date: March 2, 2026 (filed within the Form 4 two-business-day window).
- Amount: 190,034 derivative shares/options granted; reported price $0.00; reported cash value $0.
- Shares owned after transaction: not specified in the filing.
- Footnote: The underlying option vests in 48 equal monthly installments beginning February 19, 2026, subject to continued service (per footnote F1).
- Transaction type code: A (award/grant of a derivative security).
Context This was a compensation grant (derivative/option award) that vests over four years — it does not represent an immediate purchase or sale of stock and does not indicate an immediate change in market holdings. For retail investors, grants like this reflect company compensation practices more than an insider buying or selling shares; the award will only translate to actual shares if/when vested and exercised per the plan terms.